MAPT and Alzheimer disease: Patients who required additional cognitive testing and paraclinical measurements were identified, where AD patients presented with low MMSE (20.0 ± 4.5) and ACE (58.0 ± 16.5) scores and a high FAQ (11.8 ± 6.2) score, whereas paraclinical tests demonstrated elevated levels of CSF tau, p-tau (81.7 ± 25.0 ng/L) and t-tau (520.4 ± 102.4 ng/L), and decreased levels of CSF Aβ (682.8 ± 216.3 ng/L) for some of the patients, indicating extracellular tau accumulation and intracellular Aβ build-up.